In this issue of Neuron, Gasset-Rosa et al. (2017) and Grima et al. (2017) describe defects in the nuclear pore complex and impaired nucleocytoplasmic transport in Huntington's disease (HD). The findings suggest that erosion of nuclear gatekeeping function, which is found in normal brain aging, may play an important role in the pathogenesis of multiple neurodegenerative disorders, including HD.
In the mammalian neuron, the nucleus is a membrane-bound sanctuary that safeguards genomic DNA and gene transcription by shielding them from the bustling and sometime perilous molecular events in the cytoplasm. Since the majority of neurons in the brain are destined to live as long as the organism itself, there is a paramount demand for the lifelong maintenance of the integrity of the nuclear envelope and its embedded proteinaceous communication channels, called nuclear pores. Emerging evidence shows molecular links between defects in the nuclear envelope and nuclear pores in neuronal aging (Ló pez-Otín et al., 2013) and the pathogenesis of a familial form of frontotemporal dementia (FTD) or amyotrophic lateral sclerosis (ALS) (Taylor et al., 2016) . In this issue of Neuron, two studies (Gasset-Rosa et al., 2017; Grima et al., 2017 ) on Huntington's disease (HD) provide compelling evidence to strengthen the thematic link between aging and age-dependent neurodegeneration.
HD is one of the most prevalent dominantly inherited neurodegenerative disorders. HD patients suffer from a clinical triad of movement disorder, psychiatric symptoms, and cognitive impairment. The age of HD onset can be variable, but the progression of the disease is inexorable, and the patient often dies about 15 to 20 years after the onset (Bates et al., 2015) . HD is caused by a CAG repeat expansion encoding an elongated polyglutamine stretch near the N terminus of Huntingtin (HTT). Ever since the landmark discovery of HD's causal gene, the field has been studying molecular pathogenic cascades linking the simple polyglutamine repeat expansion to the plethora of HD pathogenic phenotypes, including but not limited to the selective death of striatal and cortical projection neurons. Despite the challenge of studying the very large, ubiquitously expressed mHTT gene and protein, steady progress has been made in uncovering disease mechanisms downstream of mHTT expression. For example, there is some consensus that polyglutamine-expanded mHTT elicits gain-of-function proteinopathy that may affect both nuclear and cytoplasmic cellular function (Bates et al., 2015) . Although the precise toxic species derived from the mHTT gene remains to be unequivocally established, one such species, small N-terminal polyglutamine fragments of mHTT (e.g., generated by proteolysis or alternative splicing), appear to be particularly neurotoxic (Bates et al., 2015) . These fragments can misfold and form aggregates in the nucleus and cytoplasm of HD neurons that are hallmarks of HD neuropathology. Genetic manipulations that accelerate the nuclear translocation of mHTT exacerbate disease pathogenesis in mouse models . Out of the many unanswered questions surrounding HD pathogenesis, the two new studies here shed light on the molecular pathogenic link between the nuclear and cytoplasmic disease processes in HD.
The communication between nucleus and cytoplasm is gated by the nuclear pore complex (NPC), which consists of over 30 different nucleoporin (NUP) proteins (Strambio-De-Castillia et al., 2010).
The NPC traverses the double-membrane nuclear envelope and has a central aqueous channel that gates the passive diffusion of proteins of less than 40 kilodaltons. Moreover, the NPC permits selective, directional transport of larger cargoes across the nuclear pore. Bidirectional nucleocytoplasmic transport is regulated by a subset of the NUPs lining the aqueous tunnel of the NPC. These NUPs, interacting with a variety of soluble transport factors, dictate the selectivity and direction of active macromolecular transport across the nuclear pore. One important cytosolic factor is the small GTPase Ran, which maintains a gradient of Ran-GTP that is high in the nucleus and low in the cytoplasm; such a gradient, along with its binding to transporters (i.e., karyopherins), drives many types of nuclear import and export. Importantly, the conversion of Ran-GTP to Ran-GDP by a factor called RanGAP1 on the cytoplasmic side of the NPC is a pivotal event to maintain the Ran-GTP gradient for nucleocytoplasmic transport (Figure 1 ).
Prior reports suggest nuclear envelope distortion or individual nuclear pore protein abnormalities in HD; however, comprehensive analyses of NPC pathology, particularly in models expressing full-length mHTT, was lacking until now. Gasset-Rosa et al. (2017) perform an in-depth, longitudinal analysis of nuclear membrane shape and of selected nuclear transport proteins in a knockin mouse model (zQ175) expressing one or two copies of endogenous mHTT with 190 CAG repeats, and they complement their findings with another mouse model (R6/2) expressing mHTT-exon1 and with HD-patient iPSC neurons and postmortem brains. Impressively, they found several nuclear membrane or NPC defects, including altered nuclear membrane shape, mislocalization, and aggregation of RanGAP1 and Gle1, an mRNA export factor. These aggregated nuclear pore factors appear to colocalize with mHTT aggregates in the nucleus, suggesting at least a partial sequestration and functional depletion mechanism. The latter idea is supported by the evidence that mRNA, a cargo of RanGAP1-and Gle1-mediated nuclear export, is aberrantly and progressively accumulated in the nuclei of HD mouse brains, HD patient iPSC neurons, and postmortem brains. Moreover, the study also reveals an elevated double-strand DNA break in HD mouse models. Based on the striking parallels between their findings in aging wild-type neurons and in exacerbated, aging-like phenotypes in HD neurons, Gassett-Rosa and colleagues propose the idea that mHTT may accelerate neuronal aging during disease pathogenesis.
The study by Grima et al. (2017) focuses on the NPC protein complex to test the hypothesis that mHTT may selectively impair specific NPC proteins and soluble transporters, which may play a causal role in mHTT toxicities. Using the R6/2 mouse model at an age with severe disease, they performed an exhaustive screen of nearly all the nucleoporins and NUP-associated proteins, and they found several with mislocalization. Consistent with the Gasset-Rosa work, one of the mislocalized proteins was RanGAP1; the others were Nup62 and Nup88. Importantly, the aberrant localization of these proteins-especially their partial colocalization with mHTT aggregates-is confirmed by studies in zQ175 mice and HD postmortem brains, and some aspects are confirmed in iPSC neurons with more modest CAG repeat expansion. The Grima study provides several mechanistic insights as well. First, Grima and colleagues show that reduction of mHTT aggregation appears to normalize RanGAP1 levels. Second, they establish a primary neuron model in which transient expression of full-length mHTT recapitulates the nuclear pore leakiness, the deficiency in active nuclear transport, and the mislocalization of RanGAP1. Using such a model, they showed that newly discovered HD repeat-associated non-ATG translation (RAN) (Bañ ez-Coronel et al., 2015) products are sufficient to induce nuclear import defects, reminiscent of the findings in ALS and FTD models with similar toxic RAN translation products (Taylor et al., 2016) . More importantly, they showed that overexpression of Ran or RanGAP1 in the primary neuron model and a fly model expressing a mHTT fragment can suppress mHTT cytotoxicity, reduce neurodegeneration, and improve survival. One caveat, however, is that the study did not evaluate whether such perturbation can normalize the nuclear Youthful neurons (left) exhibit a passive permeability for proteins of <40 kDa, helping to maintain a segregation of cytoplasmic, MAP2, and nuclear Ran-GTP proteins. mRNA is efficiently transported out of the nucleus. In aging neurons (center), the nuclear envelope and lamina begin to fold, pore permeability is increased, mRNA accumulates in the nucleus, and RanGAP1 aggregates on the perinuclear surface. During Huntington's disease (right), mutant Huntingtin (mHTT) aggregates in the nucleus, partially sequestering nuclear pore components NUP62, Gle1, and RanGAP1. Very large RanGAP1 perinuclear aggregates are observed, and the nuclear envelope and lamina is severely folded. Passive permeability is compromised, allowing cytoplasmic proteins such as MAP2 to leak in, and active transport is decreased, such that Ran-GTP and Ran-GDP accumulate in the cytoplasm and mRNA remains in the nucleus. transport deficits in the HD cells. Finally, Grima et al. (2017) provide a hopeful glimpse of how targeting nucleocytoplasmic transport with small molecules can improve diseased neuron survival. How efficacious such compounds are in mammalian models of HD in vivo remains unknown.
Together, the two studies provide firm evidence that compromised nuclear pore function is a consistent finding in a wide range of HD models. The molecular defects in the nuclear envelope, NPC, and nucleocytoplasmic transport are reminiscent of those found in ALS and FTD caused by hexanucleotide repeat expansion in C9ORF72 (Taylor et al., 2016) . The transcribed C9ORF72 repeat displays both RNA and protein toxicities that impair nuclear integrity and nucleocytoplasmic transport. Importantly, genetic mutations in multiple nuclear pore proteins, including Nups and RanGAP1, can suppress mutant C9ORF72 toxicities in Drosophila (Taylor et al., 2016) .
The study by Gasset-Rosa et al. (2017) also reveals a tantalizing parallel between HD neurons and aging neurons (Figure 1) . Neurons in HD knockin mice show the NPC and nuclear trafficking phenotypes and nuclear DNA breaks that are a subset of the known hallmarks of aging (Ló pez- Otín et al., 2013) . Since most of the aging-related molecular defects in heterozygous zQ175 mice are not apparent until 24 months of age, future studies are needed to assess whether all the hallmarks of aging can appear in HD neurons at an accelerated pace and whether such a phenotypic correlate is reflecting some fundamental role of mHTT in interfering with the core neuronal aging programs. Despite the lack of direct causal evidence, the role of aging as a factor in HD is gaining traction. First, studies of HD patients show that the product of CAG length and age (called the CAP score) is one of the best clinical predictors of disease progression (Bates et al., 2015) . Moreover, a recent study of an epigenetic aging clock showed that HD patient brains exhibit an accelerated aging phenotype (Horvath et al., 2016) . Thus, further studies on the detailed molecular interactions between mHTT and neuronal aging are clearly warranted.
Another critical unresolved question is how mHTT may trigger nuclear pore protein mislocalization and nuclear transport deficits. A consistent finding in the two studies is the partial colocalization of RanGAP1 and other factors (e.g., Gle1 and Nup62) with nuclear mHTT aggregates, as well as concomitant reduction of normal RanGAP1 levels. The sequestration and depletion model is supported by two lines of evidence. First, HD cells show defects in nucleocytoplasmic transport that depend on the functional Ran/RanGAP1 gradient and the failure to maintain NPC permeability barriers for cytoplasmic proteins >40 kDa, a function dependent on intact Nups. Second, overexpression of RanGAP1 suppresses mHTT toxicities in the primary neurons and the Drosophila model. However, the available data thus far are insufficient to reach incontrovertible mechanistic conclusions. For example, the formation of nuclear and cytoplasmic aggregates in the striatum of zQ175 mice occurs at a relatively early age (i.e., 4 to 6 months in the nucleus and 8 months in the cytoplasm) (Carty et al., 2015) , but the appearance of NPC protein mislocalization occurs much later (8 to 12 months). Moreover, HD iPSC neurons do not show visible aggregates but still show altered distribution of several NPC proteins. Therefore, a simple aggregate sequestration model cannot fully account for the HD NPC deficits in some instances; alternative mechanisms, such as direct interactions of mHTT with nuclear transport proteins (e.g., Shirasaki et al., 2012) or transcriptional dysregulation of NPC proteins , should be explored.
The consequence of nuclear pore leakage can be devastating in the context of HD pathogenesis. Besides the general deterioration of cellular health with NPC compromise, there may be more direct consequences on the nuclear pathogenesis of mHTT itself. Recent studies reveal the N-terminal 17 amino acids (N17) of mHTT as a key signal that confers predominant cytoplasmic localization of mHTT. Deletion of this domain in the context of a fragment (Veldman et al., 2015) or full-length mHTT greatly accelerates its nuclear aggregation and triggers severe HD-like disease phenotypes in vivo. Importantly, N17 is shown to be a nuclear export signal that is dependent on an intact Ran-GTP gradient for its proper function (e.g., Maiuri et al., 2013) . Previous studies could not pinpoint how N17 function becomes compromised in HD neurons, leading to progressive nuclear translocation and aggregation of mHTT. The current studies provide a testable model that impaired nucleocytoplasmic transport could enhance nuclear mHTT pathogenesis through increased passive leakage or diminished nuclear export, hence overcoming N17 function.
Finally, any excitement over the new insights into the pathogenesis of neurodegenerative diseases, such as the ones discussed here, has to be tempered by the sobering fact that no disease-modifying therapies are yet available for these devastating disorders. It is encouraging that small molecules indirectly targeting the nuclear transport mechanisms are shown to ameliorate mHTT toxicities in transfected primary neurons (Grima et al., 2017) . However, more studies are needed to precisely delineate the nuclear transport mechanism that is optimal to target-not only to restore the nuclear transport function, but also to improve the overall disease outcome in preclinical HD models. With growing interest in protecting the nuclear gatekeepers against assaults from aging and neurodegenerative diseases, one can anticipate with confidence that the pace of discovery will be accelerating.
